Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities

Liu, Qian; Bode, Ann M.; Chen, Xue; Luo, Xiangjian

doi:10.1016/j.bbcan.2023.189023

Cited by 5 publications

(3 citation statements)

References 178 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides, SGLT2I may act on the LMP1 induced glucose transporter 1 which reduce glucose uptake by the NPC cells. 6, 11 Meanwhile, DPP4I were hypothesized to diminish the cancer risk by eliminating the degradation of incretins, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) in the cell. 35 Although there are multiple studies regarding both SGLT2 inhibitors and DPP4 inhibitors act on cancer, the mechanism of both medications towards head and neck cancer, especially NPC, remains unclear.…”

Section: Discussionmentioning

confidence: 99%

“…5 Since most patients with NPC are diagnosed with late-stage disease, and that patients diagnosed with metastatic NPC have poor prognosis, there remains to be a need for preventing the risks of new-onset NPC. 6…”

Section: Introductionmentioning

confidence: 99%

“…8–10 EBV-encoded oncoprotein latent membrane protein 1 (LMP1) may increase the level of glucose transporter 1 and therefore enhance glucose uptake by the NPC cells and drives the Warburg effect. 6, 11 As such, SGLT2I might have help prevent NPC by playing its role in the metabolic reprogramming. However, the effects of SGLT2I on NPC on a population scale remained uncertain.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Nasopharyngeal Carcinoma and Head and Neck Cancer in Patients with Type-2 Diabetes Mellitus receiving SGLT2I, DPP4I or GLP1a: A population-based cohort study

Li,

Chou,

Mak

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: Nasopharyngeal carcinoma (NPC) remains endemic in Asian regions, which risk factors were distinct from other head and neck (H&N) cancers. Anti-diabetic drugs has been proposed to reduce the risk of NPC. The associations between sodium glucose cotransporter 2 inhibitors (SGLT2I) versus dipeptidyl peptidase-4 inhibitors (DPP4I) and the risks of NPC and H&N cancer amongst type-2 diabetes mellitus (T2DM) patients remains unknown. Method: This was a retrospective population-based cohort study including T2DM patients treated with either SGLT2I or DPP4I between 1st January 2015 and 31st December 2019 in Hong Kong. The primary outcome was new-onset NPC and other H&N cancer. The secondary outcome was cancer-related mortality. Propensity score matching (1:1 ratio) was performed using the nearest neighbour search. Multivariable Cox regression was applied to identify significant predictors. Results: This cohort included 75,884 patients with T2DM, amongst whom 28,778 patients were on SGLT2I and 47,106 patients were on DPP4I. After matching (57556 patients), 106 patients developed NPC (0.18%), and 50 patients developed H&N cancer (0.08%). Compared to DPP4I, SGLT2I was associated with significantly lower risks of NPC (Hazard ratio [HR]: 0.41; 95% Confidence interval [CI]: 0.21-0.81) but not H&N cancer (HR: 1.00; 95% CI: 0.26-3.92) after adjustments. The result remained significant regardless of demographics and obesity. The association remained consistent in different risk models, matching approaches, and the sensitivity analysis. Conclusion: This study provides real-world evidence that SGLT2I was associated with lower risks of NPC, but not H&N cancer compared to DPP4I after adjustments amongst T2DM patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Nasopharyngeal Carcinoma and Head and Neck Cancer in Patients with Type-2 Diabetes Mellitus receiving SGLT2I, DPP4I or GLP1a: A population-based cohort study

Li,

Chou,

Mak

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

Modulation of the local angiotensin II: Augmentation of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1α-HILPDA axis

Huang,

Lin,

Chen

et al. 2024

Radiotherapy and Oncology

View full text Add to dashboard Cite

Nasopharyngeal carcinoma survival by histology in endemic and non-endemic areas

Guo,

Hong,

Wang

et al. 2024

Annals of Medicine

View full text Add to dashboard Cite

Background To investigate the prognostic implications of histology among nasopharyngeal carcinoma (NPC) using the data from a Chinese cohort and the Surveillance, Epidemiology, and End Results (SEER) database. Methods We included patients diagnosed with WHO II and III subtypes NPC from two independent cohorts (Xiamen [XM]-NPC cohort and SEER-NPC cohort). Results We identified 726 patients in the XM-NPC cohort and 1334 patients in the SEER cohort. In the XM-NPC cohort, 94 (12.9%) and 632 (87.1%) patients had WHO II and III subtypes, respectively. In the SEER-NPC cohort, 839 (62.9%) and 495 (37.1%) patients had WHO II and III subtypes, respectively. WHO II subtype patients had a higher smoking rate than the WHO III subtype (57.4% vs. 43.4%) in the XM-NPC cohort. There were no significant differences in age, gender, tumor stage, or nodal stage between the two subtypes in both cohorts. In the XM-NPC cohort, patients with the WHO II subtype had worse locoregional relapse-free survival (82.2% vs. 89.5%, p = 0.063), distant metastasis-free survival (72.4% vs. 85.9%, p = 0.028), disease-free survival (61.6% vs. 78.8%, p = 0.003), and overall survival (OS) (71.7% vs. 84.0%, p = 0.035) than those with WHO III subtype. In the SEER-NPC cohort, patients with the WHO II subtype had worse NPC-specific survival (81.1% vs. 89.4%, p < 0.001) and OS (71.6% vs. 78.8%, p < 0.001) than those with WHO III subtype. The multivariate analysis showed that histology was an independent prognostic factor associated with outcomes in both cohorts. Conclusions Our study demonstrates the significant influence of histological subtypes on outcomes in NPC among various populations, highlighting substantial disparities between the WHO II and WHO III subtypes.

show abstract

Metabolic reprogramming in nasopharyngeal carcinoma: Mechanisms and therapeutic opportunities

Cited by 5 publications

References 178 publications

Nasopharyngeal Carcinoma and Head and Neck Cancer in Patients with Type-2 Diabetes Mellitus receiving SGLT2I, DPP4I or GLP1a: A population-based cohort study

Nasopharyngeal Carcinoma and Head and Neck Cancer in Patients with Type-2 Diabetes Mellitus receiving SGLT2I, DPP4I or GLP1a: A population-based cohort study

Modulation of the local angiotensin II: Augmentation of ferroptosis and radiosensitivity in nasopharyngeal carcinoma via the HIF-1α-HILPDA axis

Nasopharyngeal carcinoma survival by histology in endemic and non-endemic areas

Contact Info

Product

Resources

About